After 10 years of follow-up, cases with MRPS23/CEP17 ratio < 2 had a cumulative risk of death from breast cancer of 30% (95% CI 27–34) (Table 4; Fig. 3b), whereas cases with ratio ≥ 2 had a corresponding risk of 41% (95% CI 30–58). The gene discussed is MRPS23; the disease is breast carcinoma.